Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2024-06-28 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
Regulatory Filings Classification · 1% confidence The document is a press release dated June 28, 2024, from AB Science, announcing that the CHMP of the EMA adopted a negative opinion regarding the conditional marketing authorization application for masitinib for ALS treatment. The company states its intention to request a review of the file and details the grounds for this request, focusing on clinical trial data, tolerance, and regulatory objections. This type of announcement, detailing a significant regulatory decision (or lack thereof) and the company's immediate response/next steps regarding a drug application, is characteristic of a general regulatory update or news release concerning legal/regulatory matters, but it is not a formal financial report (like 10-K, IR, ER) nor a specific management change (MANG) or dividend notice (DIV). Since it directly addresses a regulatory outcome and the subsequent appeal process concerning a product, it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'Legal Proceedings Report' (LTR) if the focus was purely on litigation, but RNS is the broader, appropriate fallback for significant, non-standard regulatory news that isn't a core financial filing. Given the context of a specific regulatory opinion on a drug application, RNS is the most suitable classification for this type of corporate news release.
2024-06-28 French
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
Regulatory Filings Classification · 1% confidence The document is a press release dated June 28, 2024, providing an update on the application for conditional marketing authorization of masitinib by AB Science to the European Medicines Agency (EMA). It details the negative opinion received from the CHMP and the company's intention to request a re-examination, outlining the grounds for appeal (safety confirmation, GCP issues, subgroup data). This content is a specific regulatory/scientific update concerning a drug application process, not a general financial report (like 10-K or IR), an earnings announcement (ER), or a management change (MANG). It is a specific announcement regarding a regulatory/legal matter concerning the company's product development and interaction with a regulatory body (EMA/CHMP). While it touches upon clinical data, its primary function is reporting the status of a regulatory submission and the subsequent legal/procedural step (re-examination request). This fits best under Legal Proceedings Report (LTR) as it concerns regulatory action/objections, or potentially Regulatory Filings (RNS) as a general announcement. Given the focus on the regulatory outcome and the steps to contest it, LTR is a strong candidate, but since it is an update on a specific regulatory process outcome rather than a lawsuit, RNS (General regulatory announcements/fallback) is often used for such specific, non-standard regulatory updates that don't fit the core financial reports. However, LTR covers 'regulatory actions,' which this decision constitutes. Comparing LTR and RNS, LTR is more specific to disputes/actions. Given the context of challenging a regulatory decision, LTR is slightly more precise than the general RNS fallback.
2024-06-28 English
AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled "RESULTATS DE L'ASSEMBLEE GENERALE MIXTE DU 26 JUIN 2024" (Results of the Combined General Meeting of June 26, 2024) and details the voting outcomes for numerous resolutions, categorized as 'Résolutions ordinaires' and 'Résolutions extraordinaires'. This content directly corresponds to the official results of a shareholder meeting. The definition for AGM-R is 'Presentations and materials shared during the Annual General Meeting (AGM)'. While this document is the *results* rather than the *presentation*, the closest and most specific category for official voting results from a general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). DVA is defined as: 'Official results from shareholder votes at any general meeting (AGM or EGM)'. This is a perfect match for the content provided.
2024-06-27 French
AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and dated May 31, 2024. It summarizes a virtual conference held on May 30, 2024, regarding the conditional marketing authorization application for Masitinib for ALS treatment, detailing updates from the EMA and Health Canada, and discussing clinical data. This content—a summary of a specific event/update intended for immediate public dissemination—fits the description of an Earnings Release (ER) if it were financial results, but since it is a detailed operational/regulatory update summary, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the slides themselves. However, given the structure as a press release summarizing a conference call/update, and the fact that the presentation slides are mentioned as being available elsewhere, this document acts as a formal announcement of recent developments. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it is a formal announcement, RNS (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate category, although it shares characteristics with an ER/MDA summary. Given the focus on regulatory progress and the format of a press release, RNS is the safest general classification, as it is a regulatory-adjacent announcement.
2024-05-31 French
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
Call Transcript Classification · 1% confidence The document is titled "SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB...". It explicitly states it is a summary of a webcast, which is a type of conference call or presentation. The content details regulatory updates (EMA, Health Canada) and clinical data, which are typical components of an earnings or operational update call. Since the document is a summary/recap of a live event (webcast), the most appropriate classification is Call Transcript (CT), even though it is a summary rather than the full transcript, as it directly relates to the content discussed during a formal communication event. It is not a formal regulatory filing like 10-K or ER, nor is it a presentation deck (IP).
2024-05-31 English
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
Legal Proceedings Report Classification · 1% confidence The document is a press release dated May 29, 2024, from AB Science regarding an update on the regulatory status of Masitinib with the EMA's CHMP concerning ALS treatment. It announces a negative trend in the opinion and schedules a virtual conference to discuss the clinical reasons and potential appeal. The key action is the announcement of a corporate event (a conference call) to discuss regulatory/clinical developments, rather than the release of a full financial report (like 10-K or IR) or a formal regulatory filing itself. Since it is an announcement about a specific corporate event (a conference call) intended to explain developments, it most closely aligns with a general regulatory announcement or a communication aimed at investors about a significant event. Given the options, this is a general corporate announcement concerning regulatory/clinical progress. It is not a Call Transcript (CT) yet, nor is it a formal Earnings Release (ER). It is a press release detailing a significant corporate/regulatory update. The closest fit among the specific categories is either a Regulatory Filing (RNS) as a general catch-all for non-financial announcements, or potentially an Investor Presentation (IP) if the conference material is the focus, but the text itself is an announcement *about* the conference. Given the nature of discussing regulatory setbacks and upcoming investor communication, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback for a non-standard, time-sensitive corporate update that isn't explicitly financial results or a formal legal filing.
2024-05-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.